Senior agritech adviser Nicky Deasy is joining the Biotangents board on behalf of St Andrews-based investment firm Eos as an investor director.

Biotangents has developed what it says is the world’s fastest on-farm, point-of-care diagnostic device aimed at addressing disease in dairy cows.

The molecular diagnostic device can diagnose diseases such as bovine mastitis in less than two hours, with data sent to farmers’ phones and, if necessary, to their management system, vets, and milk processors.

Following the investment, Biotangents will commence on-farm trials across the UK and internationally later next year.

Fiona Marshall, CEO of Biotangents, said: “Biotangents is on the cusp of full market launch with a technology that leads to better herd health, much improved productivity, and significantly higher levels of sustainability.”

Jill Arnold, investment relationship director at Eos, said: “Scottish science that improves lives, and has global market potential, is core to our focus at Eos and Biotangents fits that criteria perfectly, not just in terms of addressing antimicrobial resistance in livestock, but also in improved animal husbandry.”

Ross McDermid, CCO at Biotangents, said: “This investment endorses our game-changing technology, and means we can now seize the huge market opportunity to support farmers, vets, and the wider dairy industry.”